The Global Healthcare Study on Atopic Dermatitis (GHSAD) is an international, multicenter observational study hosted by the University of Zurich (UZH) investigating healthcare access, treatment patterns, disease severity, and quality of life in patients with atopic dermatitis. The study collects standardized clinical data from routine medical records to identify disparities in healthcare delivery and outcomes across different healthcare systems.
The study employs a combined retrospective and prospective design, collecting data from routine clinical care and medical records spanning from January 2020 through the study conclusion.
Study Type
OBSERVATIONAL
Enrollment
9,600
University of Zurich
Zurich, Switzerland
RECRUITINGEczema Area and Severity Index (EASI)
Clinician-assessed measure of atopic dermatitis severity based on extent and severity of eczema signs; total score ranges from 0 to 72, with higher scores indicating more severe disease.
Time frame: Baseline and follow-up visits every 6-12 months for up to 5 years.
SCORing Atopic Dermatitis (SCORAD)
Clinician-assessed measure of atopic dermatitis severity incorporating extent, intensity, and subjective symptoms; total score ranges from 0 to 103, with higher scores indicating more severe disease.
Time frame: Baseline and follow-up visits every 6-12 months for up to 5 years.
Dermatology Life Quality Index (DLQI)
Patient-reported measure of dermatology-specific quality of life; total score ranges from 0 to 30, with higher scores indicating greater impairment.
Time frame: Baseline and follow-up visits every 6-12 months for up to 5 years.
Patient-Oriented Eczema Measure (POEM)
Patient-reported measure of atopic dermatitis symptoms and disease burden; total score ranges from 0 to 28, with higher scores indicating more severe disease.
Time frame: Baseline and follow-up visits every 6-12 months for up to 5 years.
Peak Pruritus Numerical Rating Scale (PP-NRS)
Patient-reported assessment of peak itch severity on a numerical rating scale from 0 (no itch) to 10 (worst imaginable itch).
Time frame: Baseline and follow-up visits every 6-12 months for up to 5 years.
Physician Global Assessment (PGA)
Clinician-assessed global measure of atopic dermatitis severity on a scale from 0 (clear) to 4 (severe).
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Time frame: Baseline and follow-up visits every 6-12 months for up to 5 years.
Body Surface Area (BSA)
Percentage of total body surface area affected by atopic dermatitis, ranging from 0% to 100%.
Time frame: Baseline and follow-up visits every 6-12 months for up to 5 years.
Patient-reported Numerical Rating Scale (NRS) for atopic dermatitis severity
Patient-reported assessment of overall atopic dermatitis severity on a numerical rating scale from 0 (no disease) to 10 (most severe disease imaginable).
Time frame: Baseline and follow-up visits every 6-12 months for up to 5 years.